Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis

This article was originally published in The Pink Sheet Daily

Executive Summary

The study found a lower risk of gastrointestinal side effects for Prexige compared to ibuprofen and naproxen, but the incidence of serious liver abnormalities was higher for the COX-2 than for the NSAIDs.
Advertisement

Related Content

Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007
Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007
Prexige 2007 Filing Target Assumes FDA Will Request Additional CV Data
Prexige 2007 Filing Target Assumes FDA Will Request Additional CV Data
Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods
FDA Will Require Additional Long-Term Data For COX-2 Inhibitors
Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis
Entire COX-2 Class Is TARGET Of Critical Lancet Editorial
Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis
Novartis Prexige NDA Re-Submission Expected In 2006; TARGET Data Are Clean, Firm Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS060336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel